editor
defend
avian
influenza
viru
possibl
adopt
treatment
develop
biodefens
overlook
biodefens
medicin
primarili
concern
respiratori
infect
bioweapon
deadliest
form
dispers
bacillu
anthraci
yersinia
pesti
caus
anthrax
plagu
highli
contagi
virus
like
smallpox
ebola
marburg
aerosol
nation
institut
health
depart
defens
fund
develop
novel
biodefens
medic
design
stimul
innat
mucos
immun
use
interferon
ifn
interferon
induc
suggest
studi
begin
immedi
explor
potenti
ifn
prevent
infect
reduc
death
caus
avian
influenza
virus
anim
model
human
modul
innat
mucos
immun
promis
rapidact
broadspectrum
approach
combat
bioterror
innat
immun
initi
respons
pathogen
potenti
capabl
erad
infect
even
innat
immun
respons
elimin
viru
may
substanti
reduc
viral
load
reduc
patholog
facilit
clear
viru
adapt
immun
respons
slow
spread
infect
biodefens
medic
ifn
ifninduc
develop
aerosol
deliveri
lung
convent
ifn
administr
inject
often
result
low
concentr
target
site
high
concentr
circul
may
caus
seriou
side
effect
aerosol
deliveri
minim
side
effect
produc
rapid
clinic
respons
inhal
ifn
proven
well
toler
benefici
rhinoviru
infect
pulmonari
tuberculosi
medic
develop
prevent
infect
caus
viral
bioweapon
diseas
includ
oral
alferon
low
dose
oral
ldo
hemispherx
biopharma
inc
philadelphia
pa
usa
inhal
intermun
brisban
ca
usa
dsrna
poli
iclc
ampligen
hemispherx
biopharma
inc
ssrna
aldara
resiquimod
pharmaceut
st
paul
mn
usa
oligonucleotid
coley
pharmaceut
group
wellesley
usa
drug
either
approv
food
drug
administr
fda
aldara
clinic
trial
alferon
ldo
inhal
resiquimod
preclin
stage
develop
ampligen
aldara
approv
genit
wart
actin
keratos
basal
cell
carcinoma
other
drug
test
aerosol
deliveri
modul
mucos
immun
respiratori
tract
could
expediti
test
inhal
intranas
administr
model
mice
ferret
pig
monkey
work
bind
receptor
activ
downstream
antivir
pathway
involv
dsrnadepend
protein
kinas
pkr
oligoadenyl
synthetasernas
l
mxa
protein
dsrna
ssrna
cpg
oligonucleotid
ligand
tolllik
receptor
tlr
modul
antivir
immun
tlr
signal
pathway
ifn
induct
cellular
level
insid
lung
drug
enhanc
phagocytot
cytolyt
activ
alveolar
macrophag
infect
establish
resist
antivir
effect
ifn
tumor
necrosi
resist
associ
nonstructur
gene
may
mechan
extraordinari
virul
therefor
prophylact
use
ifn
ifninduc
critic
combat
may
also
effect
administ
immedi
infect
ifn
resist
also
exist
viral
infect
instanc
poxvirus
includ
vaccinia
viru
encod
protein
interfer
rnasel
pkr
pathway
solubl
ifn
receptor
interfer
ifninduc
antivir
pathway
nevertheless
least
anim
model
preinfect
administr
exogen
ifn
reduc
death
poxviru
viral
load
mice
intranas
administr
prevent
lethal
vaccinia
infect
ifn
induc
poli
iclc
protect
mice
infect
influenza
viru
henc
suggest
prophylaxi
ifnstimul
innat
mucos
immun
promis
therapi
worth
immedi
investig
anim
model
second
mechan
propos
explain
virul
also
ifn
relat
cytokin
storm
shown
elev
level
proinflammatori
cytokin
includ
ifn
found
patient
die
infect
cytokin
storm
result
autoimmun
reaction
tissu
damag
septic
shock
high
ifn
dose
long
period
may
exacerb
autoimmun
howev
despit
similar
cytokin
storm
sever
acut
respiratori
syndrom
patient
respond
well
ifn
therapi
optim
formul
regimen
ifn
administr
could
crucial
effect
prophylaxi
interest
safeti
propos
initi
prophylaxi
studi
use
rel
low
ifn
dose
short
period
week
unlik
drug
effect
protect
drug
effect
might
work
everyon
genet
polymorph
influenc
ifn
respons
howev
fda
approv
even
one
might
save
mani
live
